Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
OwnerSimon BARRY, Elza DE BRUIN +3inventors
InventorsSimon BARRY, Elza DE BRUIN, Andrew FOXLEY, Amy MCDONOUGH, Gaia SCHIAVON
Life of this patent
Estimating the term…
Abstract
The specification relates to therapeutic combinations of capivasertib, a CDK4/6 inhibitor (such as palbociclib, ribociclib or abemaciclib) and fulvestrant that are useful for treating breast cancer, and to methods of treating breast cancer patients with combinations of capivasertib, a CDK4/6 inhibitor (such as palbociclib, ribociclib or abemaciclib) and fulvestrant.
Claims34
A method of treating a patient having hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer, comprising administering to the patient a combination therapy comprising a first amount of capivasertib, a second amount of a CDK4/6 inhibitor and a third amount of fulvestrant, wherein the first amount, second amount and third amount together comprise a therapeutically effective amount.
Dependencies are inferred from the claim text.